EUVIMEDEUVIMED entdecken
Crossref

Development of glutamatergic antipsychotics requires efficient synaptic glutamatergic transmission while preventing NMDA receptor down‐regulation and overactivation of extrasynaptic transmission

Ruri Okubo iD, Tomoka Oka iD, Eishi Motomura iD, Motohiro Okada iD

British Journal of Pharmacology · 2026-12 · 183 (23) · 6749-6766

DOI: 10.1111/bph.70646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 13.08.2026. Verfasst von Ruri Okubo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate, Antipsychotic Agents, Synaptic Transmission, Glutamic Acid. Die Arbeit nennt 63 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Clozapine and d ‐cycloserine improve negative symptoms of treatment‐resistant schizophrenia, whereas combined administration of d ‐cycloserine plus clozapine aggravates them. However, the underlying mechanisms of these inconsistent effects remain unclear. Experimental Approach Effects of chronic administration of MK‐801 (0.1 mg·kg −1 ·day −1 ), d ‐cycloserine (2 mg·kg −1 ·day −1 ), clozapine (5 mg·kg −1 ·day −1 ) and memantine (10 mg·kg −1 ·day −1 ) for 14 days on sucrose preference, GluN2A/GluN2B expression and basal and N ‐methyl‐ d ‐aspartate (NMDA)‐evoked releases of l ‐glutamate/ d ‐serine in the orbitofrontal cortex of male rats were determined. Key Results Chronic MK‐801 administration decreased sucrose preference, GluN2A/GluN2B expression and NMDA‐evoked release but increased basal extracellular l ‐glutamate/ d ‐serine levels in the orbitofrontal cortex. Chronic administration of clozapine or d ‐cycloserine restored MK‐801‐induced sucrose preference impairments and NMDA‐evoked release but left unaffected basal extracellular levels or GluN2A/GluN2B expression. Conversely, combined administration of clozapine + d ‐cycloserine further enhanced the MK‐801‐induced sucrose preference impairments, NMDA‐evoked releases and GluN2A/GluN2B expressions and the increasing basal extracellular levels. Adding memantine to MK‐801 + clozapine or MK‐801 + clozapine + d ‐cycloserine reversed the sucrose preference, NMDA‐evoked release and GluN2A/GluN2B expressions and the increasing basal extracellular levels. Tachyphylactic dose of d ‐cycloserine (25 mg·kg −1 ·day −1 ) decreased GluN2A/GluN2B expression, which was antagonised by the glycine‐binding‐site inhibitor MDL29951(10 mg·kg −1 ·day −1 ). Clozapine suppressed PP2A signalling. Chronic monotherapy with d ‐cycloserine or PP2A inhibitor LB‐100 (1.5 mg·kg −1 ·day −1 ) left unaffected GluN2A/GluN2B expression, whereas their combined administration down‐regulated them. Conclusion and Implications These results suggest that potentiation of the NMDA receptor is involved in improving negative symptoms, but down‐regulating NMDA receptor and enhanced extrasynaptic‐NMDA receptor conversely contribute to the aggravation of negative symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateAntipsychotic AgentsSynaptic TransmissionGlutamic AcidAnimalsMaleClozapineCycloserineDown-RegulationDizocilpine MaleateRatsRats, Sprague-DawleyPrefrontal CortexMemantineSerine

Stichwörter der Autor:innen

NMDA/glutamate receptorclozapined‐cycloserinepathophysiologytreatment‐resistant schizophrenia

Substanzen

Receptors, N-Methyl-D-AspartateAntipsychotic AgentsClozapineCycloserineGlutamic AcidDizocilpine MaleateMemantineSerine

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Mie, Japan.

ORCID-Profile: Ruri Okubo, Tomoka Oka, Eishi Motomura, Motohiro Okada

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Okubo, R., Oka, T., Motomura, E., & Okada, M. (2026). Development of glutamatergic antipsychotics requires efficient synaptic glutamatergic transmission while preventing NMDA receptor down‐regulation and overactivation of extrasynaptic transmission. British Journal of Pharmacology, 183(23), 6749-6766. https://doi.org/10.1111/bph.70646

Vancouver

Okubo R, Oka T, Motomura E, Okada M. Development of glutamatergic antipsychotics requires efficient synaptic glutamatergic transmission while preventing NMDA receptor down‐regulation and overactivation of extrasynaptic transmission. British Journal of Pharmacology. 2026;183(23):6749-6766. doi:10.1111/bph.70646

BibTeX
@article{Okubo2026,
  author = {Okubo, Ruri and Oka, Tomoka and Motomura, Eishi and Okada, Motohiro},
  title = {Development of glutamatergic antipsychotics requires efficient synaptic glutamatergic transmission while preventing NMDA receptor down‐regulation and overactivation of extrasynaptic transmission},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {23},
  pages = {6749--6766},
  doi = {10.1111/bph.70646}
}
Kostenlos starten →